Aletheia Neuroenergetics
harnesses the power of gene therapy to treat neurodegenerative diseases
First-in-Class Gene Therapy
Aletheia is developing gene therapies based on neuroenergetics – increasing the production of energy to restore neural function
LEAD INDICATION: ALS
Aletheia is developing a gene therapy which augments neuronal energy demands to slow the progression of Amyotrophic Lateral Sclerosis (ALS) & restore neural function
About ALS
Amyotrophic Lateral Sclerosis (ALS) is caused by the relentless degeneration of motor neurons in the brain and spinal cord resulting in paralysis and death
​
Aletheia is developing a gene therapy which creates a novel metabolic pathway to significantly restore energy production and neural function
​
Aletheia has the potential to leverage its leading technology platform to develop and commercialize products targeting other neurological disorders which require uninterrupted supply of energetic currency for metabolic homeostasis
Neuroenergetics
In ALS, there is universal disruption of metabolism in diseased neurons leading to loss of energy production, which contributes to neuronal dysfunction & degeneration
​
The augmentation of neuroenergetics has utility for ALS as well as numerous other neurological disorders
Innovative Platform for CNS Diseases
Aletheia has the potential to leverage its leading technology platform to develop and commercialize products targeting other neurological disorders which require uninterrupted supply of energetic currency for metabolic homeostasis
